References
- NaidooPRambiritchVButkowNSamanSOptimal utilisation of sulphonylureas in resource-constrained settingsCardiovasc J Afr2014252838524844554
- RambiritchVNaidooPButkowNDose–response relationships of sulfonylureas: will doubling the dose double the response?South Med J2007100111132113617984746
- RambiritchVPillaiGMaharajBRobertsonLIGlibenclamide – what dose?S Afr Med J2007977474
- CrossJLeeHWestelinckANelsonJGrudzinskasCPeckCPost-marketing drug dosage changes of 499 FDA-approved new molecular entities, 1980–1999Pharmacoepidemiol Drug Saf20021143944612426927
- BreimerDDDanhofMRelevance of the application of pharmacokinetic/pharmacodynamic modeling concepts in drug development. The ‘wooden shoe’ paradigmClin Pharmacokinet1997322592679113436
- GroopLGroopP-HStenmanSComparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatmentDiabetes Care19871066716783123184
- RambiritchVMaharajBNaidooPGlibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation studyClin Pharmacol20146636924741335
- Hamid-AbdelMESuleimanMSel-SayedYMNajibNMHasanMMA rapid high performance liquid chromatography assay of glibenclamide in serumJ Clin Pharm Ther19891431811882503528
- RambiritchVMaharajBNaidooPPillaiGPopulation pharmacokinetic modeling of glibenclamide in South African type 2 diabetic subjectsClin Pharmacol20168839227471411
- RydbergTJonssonAKarlssonMOMelanderAConcentration–effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamicsBr J Clin Pharmacol19974343733819146849
- TracewellWGStalkerDJMaloleyPAGallagherTFGwiftPRPopulation pharmacokinetics of glyburide in patients with well controlled diabetesPharmacotherapy199818151569469681
- KrzyzanskiWChakrabortyAJuskoWJAlgorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response modelsChronobiol Int2000171779310672436
- GroopLCBarzilaiNRatheiserKDose-dependent effects of glyburide on insulin secretion and glucose uptake in humansDiabetes Care19911487247271954808
- FeldmanJMGlyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effectsPharmacotherapy19855243623923453
- HuizarJFGonzalezLAAldermanJSmithHSSulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabeticsJ Am Coll Cardiol20034261017102113678923